FDA Recommends New Trial for Tovecimig Prior to BTC BLA

Compass Therapeutics (CMPX) received FDA feedback requesting a new study to demonstrate survival benefits before allowing a Biologics License Application (BLA) for tovecimig in biliary tract cancer, though the company remains confident in its current data and intends to continue engagement with the agency.